Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:07 2025-01-13 am EST			5-day change	1st Jan Change
90.79 ^CHF	-0.33%		+2.06%	+2.36%

06:27pm	Swiss Stocks Close Lower Ahead of Key Inflation, Economic Data	MT
05:04pm	Global markets live: Apple, Johnson & Johnson, Meta, Amazon, The Hershey, Eli Lilly...

Novartis Wins EU Approval for Expanded Use of Kisqali in Breast Cancer Treatment

November 27, 2024 at 05:21 am EST

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Novartis AG

Swiss Stocks Close Lower Ahead of Key Inflation, Economic Data	12:27pm	MT
Global markets live: Apple, Johnson & Johnson, Meta, Amazon, The Hershey, Eli Lilly...	11:04am
Illumina Starts Pilot Program With Partners to Generate Proteomics Data	04:44am	MT
Novartis: Favourable court ruling on Entresto	02:48am	CF
Novartis's U.S. Patent for Entresto Upheld by Appeals Court	01:49am	DJ
US Court Upholds Validity of Novartis' Combination Patent for Entresto	01:30am	MT
Novartis Entresto(R) US patent upheld by US Court of Appeals	01:15am	DJ
NOVARTIS AG : Goldman Sachs remains Neutral	Jan. 09	ZD
Light Horse Therapeutics Inc announced that it expects to receive $87 million in funding from Versant Venture Management, LLC, Bristol-Myers Squibb Company, AbbVie Ventures, Inc., Taiho Ventures, LLC, Mubadala Capital, Novartis AG	Jan. 08	CI
NOVARTIS AG : Gets a Neutral rating from Berenberg	Jan. 07	ZD
NOVARTIS AG : Bernstein reiterates its Buy rating	Jan. 07	ZD
A poor 2024 increases the odds of a brighter 2025	Jan. 02
Experts expect more IPOs and takeovers in 2025	Jan. 02	RE
Swiss Stocks Close Higher Ahead of New Year Break	Dec. 30	MT
Novartis Says Gene Therapy for Spinal Muscular Atrophy Meets Primary Endpoint in Phase 3 Study	Dec. 30	MT
Novartis' Late-stage Study for Spinal Muscular Atrophy Therapy Meets Primary Endpoint	Dec. 30	MT
Novartis' Late-stage Study for Spinal Muscular Atrophy Therapy Meets Primary Endpoint	Dec. 30	MT
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA	Dec. 30	DJ
Novartis Announces Positive Topline Results from the Phase III Steer Study	Dec. 30	CI
Sector Update: Health Care Stocks Lower in Late Afternoon Trading	Dec. 27	MT
Sector Update: Health Care	Dec. 27	MT
Novartis Must Face Claims Alleging Kickbacks for MS Drug Promotion, US Appeals Court Rules	Dec. 27	MT
Novartis Must Face Claims Alleging Kickbacks for MS Drug Promotion, Appeals Court Rules	Dec. 27	MT
Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules	Dec. 27	RE
Novartis to Close MorphoSys Sites, Affecting 330 Jobs	Dec. 19	MT

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Employees

76,057

Sector

Pharmaceuticals

Calendar

2025-01-12 - JP Morgan Healthcare Conference

More about the company